Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress
October 23 2019 - 08:00AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced presentations on the company’s gene
therapy programs to be presented at the European Society of Gene
and Cell Therapy (ESGCT) 2019 Congress in Barcelona, Spain.
Data Presentations at the ESGCT Annual
Meeting Oral Presentation Title:
Intravitreal gene therapy with ADVM-022 for neovascular age-related
macular degeneration (OPTIC phase 1 trial – encore
presentation)Abstract Number: OR21Date: October 24, 2019Time: 2:45
– 4:45 pm CET
Poster Title: In vivo screening of an
adeno-associated virus capsid library in non-human primate eyes
identifies a novel AAV variant with superior retinal penetration
and transduction by intravitreal delivery Abstract Number: P004
Date: October 24, 2019 Time: 1:00 – 2:30 pm CET Poster
Title: Biodistribution and pharmacokinetics of
AAVrh.10-A1AT mediated gene therapy in humanized-liver mice as a
predictor of A1AT human expression levels following intravenous
deliveryAbstract Number: P426 Date: October 24, 2019 Time:
1:00 – 2:30 pm CET
Poster Title: Feasibility of Gene
Therapy for Friedreich Ataxia-Associated Cardiomyopathy in
Non-Human Primates: Evaluation of Delivery Route, Biodistribution
and Expression Following AAVRh.10.FXN
AdministrationAbstract Number: P480 Date: October 24,
2019 Time: 1:00 – 2:30 pm CET
About ADVM-022 Gene TherapyADVM-022 utilizes a
propriety vector capsid, AAV.7m8, carrying an aflibercept coding
sequence under the control of a proprietary expression cassette.
ADVM-022 is administered as a one-time intravitreal injection,
designed to deliver long-term efficacy, reduce the burden of
frequent anti-VEGF injections, optimize patient compliance, and to
improve vision outcomes for wet AMD and diabetic retinopathy
patients.
In recognition of the need for new treatment options for wet
AMD, the U.S. Food and Drug Administration granted Fast Track
designation for ADVM-022 for the treatment of this disease.
Adverum is currently evaluating ADVM-022 in the OPTIC study, a
phase 1 clinical trial in patients 50 years and older with wet AMD.
Additionally, Adverum plans to submit an Investigational New Drug
Application for ADVM-022 for the treatment of diabetic retinopathy
to the U.S. Food and Drug Administration in the first half of
2020.
About Adverum Biotechnologies, Inc.Adverum
Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy
company targeting unmet medical needs for serious ocular and rare
diseases. Adverum is evaluating its novel gene therapy candidate,
ADVM-022, as a one-time, intravitreal injection for the treatment
of its lead indication, wet age-related macular degeneration. For
more information, please visit www.adverum.com
Forward-looking StatementsStatements contained
in this press release regarding events or results that may occur in
the future are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements include but are not limited to statements regarding:
Adverum’s plans for advancing ADVM-022; the potential benefits of
ADVM-022, all of which are based on certain assumptions made by
Adverum on current conditions, expected future developments and
other factors Adverum believes are appropriate in the
circumstances. Adverum may not achieve any of these in a timely
manner, or at all, or otherwise carry out the intentions or meet
the expectations disclosed in its forward-looking statements, and
you should not place undue reliance on these forward-looking
statements. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include risks inherent to, without limitation: Adverum’s novel
technology, which makes it difficult to predict the time and cost
of product candidate development and obtaining regulatory approval;
the results of early clinical trials not always being predictive of
future results; the potential for future complications or side
effects in connection with use of ADVM-022; obtaining regulatory
approval for gene therapy product candidates; enrolling patients in
clinical trials; reliance on third parties for conducting the OPTIC
trial and vector production; and ability to fund operations through
completion of the OPTIC trial and thereafter. Risks and
uncertainties facing Adverum are described more fully in Adverum’s
Form 10-Q filed with the SEC on August 8, 2019 under the heading
“Risk Factors.” All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Adverum undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Investor and Media Inquiries:
Investors:Myesha LacyAdverum BiotechnologiesVice President,
Investor Relations and Corporate
Communicationsmlacy@adverum.com1-650-304-3892
Media:Cherilyn Cecchini, M.D.Account
Supervisorccecchini@lifescipublicrelations.com
646-876-5196
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2023 to Mar 2024